NCT06330012View on ClinicalTrials.gov

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

December 31, 2027

Conditions
HER2-positive Breast Cancer
Interventions
DIAGNOSTIC_TEST

GeoMx data analysis with clinical outcome

"1. List of HER2 positive breast cancer~ * Stage IV disease~ * Treated with T-Dxd~ * Available FFPE samples~2. Prepare tissue for digital spatial proteomics~ * FFPE/H\&E slide~ * Region of Interest(ROI) check~ * Make a Tissue microarray~ * Prepare special slide for GeoMx~3. GeoMx data analysis with clinical outcome"

Trial Locations (1)

06351

RECRUITING

Ji-Yeon Kim, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER